- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | SCIBASE: The exercise price for warrants of series TO 3 has been determined | 2 | Cision News | ||
| 07.11. | SciBase: Interim report | 193 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ --
January 1 - September 30, 2025
The third quarter in figures
Net sales were TSEK 10,339 (8,408), +23%, cleared... ► Artikel lesen | |
| 07.11. | The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million | 238 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534... ► Artikel lesen | |
| 07.11. | SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million | 267 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase... ► Artikel lesen | |
| 22.10. | Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2026 | 192 | PR Newswire | STOCKHOLM, Oct. 22, 2025 /PRNewswire/ -- The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2026:
Anders... ► Artikel lesen | |
| 26.09. | SciBase: Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis | 293 | PR Newswire | STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication... ► Artikel lesen | |
| 23.09. | SciBase receives initial order for clinical study from Castle Biosciences | 309 | PR Newswire | STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has... ► Artikel lesen | |
| 10.09. | Main owners strengthen their position in SciBase | 316 | PR Newswire | STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet... ► Artikel lesen | |
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 28.08. | SciBase: New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense | 304 | PR Newswire | STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication... ► Artikel lesen | |
| 19.08. | SciBase: Interim report | 370 | PR Newswire | STOCKHOLM, Aug. 19, 2025 /PRNewswire/ --
January 1 - June 30, 2025
The second quarter in figures
Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.The... ► Artikel lesen | |
| 01.08. | SciBase announces outcome in directed share issue | 394 | PR Newswire | STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation... ► Artikel lesen | |
| 09.07. | SciBase Launches Nevisense Pilot at Leading University in Southeast Florida | 270 | PR Newswire | STOCKHOLM, July 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a... ► Artikel lesen | |
| 07.07. | SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense. | 320 | PR Newswire | STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce... ► Artikel lesen | |
| 30.06. | SciBase announces outcome in directed share issue | 216 | PR Newswire | STOCKHOLM, June 30, 2025 /PRNewswire/ -- On 23 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, pursuant to the... ► Artikel lesen | |
| 23.06. | SciBase resolves on a directed share issue of approximately SEK 11 million | 349 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 435 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 406 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 465 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 81,96 | -0,09 % | Access Advance Applauds Historic Preliminary Injunction in German HEVC Enforcement Action Against Roku | BOSTON, MA / ACCESS Newswire / November 24, 2025 / Access Advance LLC today announced that one of its Licensors, Dolby International AB, has obtained a historic preliminary injunction from the Landgericht... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,093 | +8,14 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 87,20 | -0,68 % | Boston Scientific's Margins Strengthen in Q3: What's Driving It? | ||
| PAUL HARTMANN | 221,00 | -0,45 % | Januar bis September 2025: PAUL HARTMANN steigert Umsatz trotz schwächerer Absatzmärkte | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.826,0 Mio. EUR, organisches Umsatzwachstum von 2,0 % - Bereinigtes EBITDA liegt bei 195,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,7 % - Unternehmen... ► Artikel lesen | |
| SYSMEX | 9,050 | +1,69 % | Sysmex verfehlt Q2-Prognosen - Aktie bricht ein | ||
| ADDLIFE | 16,560 | +1,22 % | AddLife AB: Interim Report January 1 - September 30, 2025 | Good organic growth and strong earnings development"AddLife's companies performed strongly during the quarter. Organic growth was solid, margin improvement continued, earnings increased significantly... ► Artikel lesen | |
| EMBECTA | 11,600 | -1,69 % | Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance | PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month... ► Artikel lesen | |
| ENOVIS | 25,600 | -3,03 % | Enovis Corporation: Enovis Announces Third Quarter 2025 Results | Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically... ► Artikel lesen | |
| KANGJI MEDICAL | 1,033 | -100,00 % | XFRA 50J: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKANGJI MED.HLDS... ► Artikel lesen | |
| PULMONX | 1,400 | +13,82 % | Pulmonx Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| SI-BONE | 16,800 | -1,75 % | SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance | Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the... ► Artikel lesen | |
| KOOTH | 1,370 | -1,44 % | Kooth übernimmt US-Plattform für Kinder-Teletherapie | ||
| PEIJIA MEDICAL | 0,605 | 0,00 % | Peijia Medical Announces 2025 Interim Results | HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets... ► Artikel lesen | |
| LIFECARE ASA | 0,399 | +1,01 % | Lifecare ASA: Financial calendar | ||
| BACTIGUARD | 1,335 | -1,48 % | Bactiguard Holding AB: Bactiguard Holding AB's interim report third quarter 2025 | Continued profitability and clinical evidence supporting future growth
Third quarter 2025 (July - September)
Total revenue amounted to SEK 48.4 (73.9) million, a decrease of SEK 25.5 million corresponding... ► Artikel lesen |
SCIBASE HOLDING AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,042 (+21.000 %) liegt der Kurs bei 0,042 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.